EDX Medical backs large-scale prostate cancer testing in Scotland

EDX Medical Group plc

EDX Medical Group is supporting a major prostate cancer testing initiative in Scotland that will offer free tests to men aged 40 to 80 during 2026. The Scottish Prostate Cancer Initiative aims to test 25,000 men, helping to identify cases earlier and gather data that may support future screening and treatment decisions.

Rather than being limited to laboratory development or internal research, the company’s diagnostic work is being applied in a real-world setting at meaningful scale.

The process is designed to be simple for participants. Men provide a blood sample, with no physical examination required. Results are sent directly and confidentially within 48 hours, along with guidance on any next steps. This approach helps reduce common barriers to testing, such as inconvenience, embarrassment or uncertainty about the process.

After the initial PSA testing, selected samples will undergo additional innovative diagnostic tests for research purposes. The goal is to collect data that could help shape future screening and treatment protocols.

The initiative is being run with the Graham Fulford Charitable Trust, a prostate health awareness charity. This partnership brings together public health outreach and diagnostic capability. It may help the programme reach men who might otherwise avoid or delay testing, which is important because early detection can improve treatment options. The project is also supported by Scottish sporting figures, businesses and organisations, giving it wider visibility across the target population.

EDX Medical Group plc (LON:EDX) is a UK-based listed company focused on the development of diagnostic tests that enable personalised treatment for cancer, cardiovascular and infectious diseases.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

EDX Medical appoints Martin Walton as Chief Executive Officer

EDX Medical has appointed Martin Walton as CEO with immediate effect, succeeding co-founder Dr Michael Hudson, who will continue...

EDX Medical adds diagnostics experts to Board as company targets commercial growth

EDX Medical Group has appointed Dr Joanne Hackett and Peter Collins as non-executive directors, bringing senior expertise in diagnostics,...

EDX Medical launches AI breast cancer test in UK

EDX Medical Group has partnered with Caris Life Sciences to introduce the Caris MI Clarity test in the UK....

EDX Medical Founder increases shareholding with 197,500 share purchase

EDX Medical founder and Chief Scientific Officer Professor Sir Christopher Evans has bought 197,500 shares in the company, taking...

EDX Medical Founder Sir Christopher Evans to present at London investor event

EDX Medical Group has announced that Founder and Chief Scientific Officer Professor Sir Christopher Evans OBE will present at...

EDX Medical appoints biotech industry veteran Professor Michael Owen as Chairman

EDX Medical Group has appointed Professor Michael Owen as non-executive Chairman with immediate effect, succeeding Jason Holt. The former...

Search